Quarterly ResultMay 6, 2026, 08:03 AM
UroGen Pharma Q1 Revenue $51.0M, ZUSDURI Sales +109% to $29.2M
AI Summary
UroGen Pharma reported strong financial results for Q1 2026, with total revenue surging 152% year-over-year to $51.0 million. This growth was primarily driven by ZUSDURI, which generated $29.2 million in revenue, marking a 109% quarter-over-quarter increase due to broader utilization with a permanent J Code. JELMYTO also contributed with $21.7 million in revenue, up 7% year-over-year. The company continues to advance its pipeline, with UGN-103 on track for NDA submission in H2 2026 and UGN-501 IND submission planned for Q2 2026.
Key Highlights
- ZUSDURI revenue grew 109% quarter-over-quarter to $29.2 million in Q1 2026.
- JELMYTO revenue increased 7% year-over-year to $21.7 million in Q1 2026.
- Total revenue for Q1 2026 was $51.0 million, up 152% year-over-year.
- Net loss improved to $23.6 million, or ($0.47) per share, in Q1 2026 from $43.8 million, or ($0.92) per share, in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $140.3 million as of March 31, 2026.
- R&D expenses decreased to $15.6 million in Q1 2026 from $19.9 million in Q1 2025.
- SG&A expenses increased to $51.5 million in Q1 2026 from $35.0 million in Q1 2025.
- Expanded debt facility with Pharmakon Advisors included a $200 million tranche funded in Q1 2026.